Total Clarity Wealth Management’s Iovance Biotherapeutics IOVA Stock Holding History

Total Clarity Wealth Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-557	Closed	-$11K	–	548
2021 Q4	$11K	Hold	557	–	–	0.01%	670
2021 Q3	$14K	Buy	+557	New	+$13.1K	0.01%	608
2021 Q2	–	Sell	-1,897	Closed	-$60K	–	445
2021 Q1	$60K	Buy	+1,897	New	+$78.6K	0.03%	311
2020 Q1	–	Sell	-320	Closed	-$9K	–	344
2019 Q4	$9K	Buy	+320	New	+$7.28K	0.01%	511

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Total Clarity Wealth Management's IOVA Position: Q1 2022 in Review

Total Clarity Wealth Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 557 shares — an estimated $11K sold.

Total Clarity Wealth Management first reported a position in IOVA in Q4 2019 and held it in 4 quarters. The position peaked at $60K in Q1 2021. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

Total Clarity Wealth Management reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 557 Iovance Biotherapeutics shares in Q1 2022, an estimated $11K.
Total Clarity Wealth Management first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 4 quarters.
Total Clarity Wealth Management's Iovance Biotherapeutics position peaked at $60K in Q1 2021.
250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Total Clarity Wealth Management's 13F filing for Q1 2022, filed 29 Apr 2022.